Novel function of α1D L-type calcium channel in the atria

Ujala Srivastava1, Ademuyiwa S Aromolaran1, Frank Fabris1

  • 1Cardiovascular Research Program, VA New York Harbor Healthcare System and Departments of Medicine, Cell Biology and Pharmacology, USA; State University of New York Downstate Medical Center, Brooklyn, NY, USA.

Insights

The atrial L-type calcium channel alpha1D (α1D) interacts with the SK4 channel, regulating atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) secretion. Deleting α1D reduces SK4 expression and BNP release, suggesting a novel role in atrial endocrine function and potential therapeutic targets for arrhythmias.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Physiology

Background:

  • Atrial L-type Calcium channels (α1C and α1D) regulate cardiac functions, including hormone release (ANP, BNP).
  • The α1D Ca channel is atrial-specific and implicated in atrial fibrillation pathogenesis.
  • The small conductance calcium-activated potassium channel, SK4, is also atrial-specific and involved in ANP/BNP secretion, but its cardiac role is unclear.

Purpose of the Study:

  • To investigate the functional interaction between SK4 channels and α1D Ca channels.
  • To determine the role of SK4 in α1D-dependent ANP and BNP secretion.
  • To explore the impact of α1D deletion on SK4 expression and atrial hormone secretion.

Main Methods:

  • Utilized α1D gene heterozygous (α1D+/-) mice and HL-1 cardiomyocytes.
  • Performed immunoprecipitation and western blotting to confirm α1D-SK4 interaction.
  • Employed RT-PCR to assess gene expression (Cacna1d, Kcnn4).
  • Measured BNP serum levels and secretion in response to endothelin and mechanical stretch.

Main Results:

  • Confirmed physical interaction between α1D and SK4 channels.
  • Observed decreased α1D and SK4 mRNA expression in α1D+/- mice.
  • Documented a significant reduction in BNP serum levels in α1D+/- mice.
  • Demonstrated a substantial decrease in BNP secretion in α1D-knockdown HL-1 cells.

Conclusions:

  • α1D Ca and SK4 channels are physically coupled in atrial cells.
  • α1D channel deletion leads to reduced SK4 expression and atrial natriuretic peptide secretion.
  • This study reveals a novel role for α1D in atrial endocrine function, identifying potential therapeutic targets for cardiac arrhythmias like atrial fibrillation.

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
2.1K
G-Protein Gated Ion Channels01:21

G-Protein Gated Ion Channels

GPCRs are primarily responsible for our sense of smell, taste, and vision.  The binding of a sensory stimulus activates GPCR to stimulate effector proteins, many of which are ion channels in the sensory organs. GPCRs modulate the opening and closing of the target ion channels either directly by binding them, or by releasing second messengers that activate these channels. As ions move across the membrane, the membrane potential is altered, which induces an appropriate response.
Sensory...
6.5K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.5K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.7K
Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
2.5K
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
3.2K